Clinical Trials Logo

Clinical Trial Summary

This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer.


Clinical Trial Description

This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer. Three dose levels of HBI-8000 (15 mg, 20 mg, and 25 mg) will be tested using a standard 3+3 escalation plan with an expanded cohort at the maximum tolerated dose (MTD) to enroll a minimum of 10 patients evaluable for safety to fulfill the requirements for moving the combination forward to I-SPY 2 trial. To be considered evaluable for safety, the patient must receive at least 75% of their prescribed regimen per cycle for 4 consecutive cycles with a cycle of therapy defined as 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress at 9 weeks evaluation or later but before completing 4 cycles and who have only experienced Grade ≤ 1 toxicities (excluding alopecia) will also be considered evaluable for safety. Enrolled patients will remain on their assigned dose level until unacceptable toxicity or disease progression occurs. During dose escalation phase, if more than 34% of the evaluable patients at a dose level experience dose limiting toxicities (DLT), this dose level will be considered having exceeded MTD. Once MTD is identified during dose escalation phase, the MTD dose level will be expanded in the expansion phase to enroll additional patients to ensure that at least 10 patients are evaluable for safety at the MTD. Paclitaxel and trastuzumab are administered by intravenous (IV) infusion on days 1, 8, 15, and 22 of a 28-day cycle. HBI-8000 will be taken by mouth twice weekly at the assigned dose on days 1, 4, 8, 11, 15, 18, 22 and 25 of a 28-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient refusal/non-compliance is observed. The study will evaluate the safety and tolerability of oral HBI-8000 bi-weekly in combination with weekly paclitaxel and trastuzumab and if successful, determine an optimal dose to move into phase II testing of this combination in the I-SPY 2 trial in a neo-adjuvant breast cancer population. To determine the MTD of HBI-8000 twice weekly in combination with weekly paclitaxel and trastuzumab in women with HER2+ breast cancer. - To determine the adverse event rate of twice weekly HBI-8000 in combination with weekly paclitaxel and trastuzumab - To determine the tolerability of twice weekly HBI-8000 when administered with weekly paclitaxel and trastuzumab - To explore efficacy of twice weekly HBI-8000 in combination with weekly paclitaxel and trastuzumab - To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with weekly paclitaxel and trastuzumab. - To determine the on-target effect of HBI-8000 by measuring protein acetylation - To explore the treatment effects on immune cells in blood and/or tumor tissue as appropriate Enrolled patients will take HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles). On the day of paclitaxel infusion, HBI-8000 is taken at least one hour before paclitaxel infusion. HBI-8000 should be taken within 30 minutes after a meal. The interval between HBI-8000 administrations is 3-4 days in the absence of dose delay or interruptions due to adverse events. For example, three days should elapse between the 1st and 2nd dose of HBI-8000 of the week, such as Monday/Thursday; Tuesday/Friday. A disease re-evaluation will be scheduled every 8 weeks. Based on the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1), response to treatment will be determined. Patients with stable disease (SD), partial response (PR) or complete response (CR) may continue treatment until disease progression, unacceptable side effects, or patient refusal/non-compliance occurs. Patients will be monitored in clinic every 4 weeks while receiving study treatment. The end of treatment (EOT) visit will occur at 4 weeks after the last dose of HBI-8000, or before the start of a new anti-cancer therapy, whichever is earlier. At EOT, patients will be evaluated for resolution of treatment related toxicities. Toxicity related to HBI-8000, if not yet resolved to Grade ≤ 1, will be followed until resolution to Grade ≤ 1 or considered chronic. All patients will be followed up to 1 year from study enrollment for best objective response, duration of response, time to PD, and survival. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02569489
Study type Interventional
Source HUYABIO International, LLC.
Contact
Status Withdrawn
Phase Phase 1
Start date December 2015
Completion date December 2015

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2